Inhibrx, Inc.
DelistedCIK 1739614fmd_0M7Q5WJ1Q20KMTN8FEE65AST3NManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Mar 31, 2024, 21 periods
Latest annual · FY2023
Millions- Total revenues
- 2
- Operating income
- (219)
- Net income
- (241)
- Free cash flow
- (198)
Latest quarter · Q1 FY2024
Millions- Total revenues
- 0
- Operating income
- (74)
- Net income
- (79)
- Free cash flow
- (64)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -48.1%
Inhibrx, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $1.8 million | $2.2 million | -17.9% | 10-K 2024-02-28 · proof |
| Operating income | -$219.2 million | -$129.1 million | 10-K 2024-02-28 · proof | |
| Net income | -$241.4 million | -$145.2 million | 10-K 2024-02-28 · proof | |
| Cash from operating activities | -$193.3 million | -$115.3 million | 10-K 2024-02-28 · proof | |
| Free cash flow | -$197.9 million | -$116 million | 10-K 2024-02-28 · proof | |
| Total assets | $307.9 million | $290.9 million | +5.9% | 10-K 2024-02-28 · proof |
| Total liabilities | $264.4 million | $232.8 million | +13.6% | 10-K 2024-02-28 · proof |
| Cash and cash equivalents | $277.9 million | $273.9 million | +1.5% | 10-K 2024-02-28 · proof |
| Total debt | $207 million | 10-Q 2024-05-09 · proof |
- What was Inhibrx, Inc.'s revenue in fiscal 2023?
- Inhibrx, Inc. reported revenue of $1.8 million for fiscal 2023 (the year ended Dec 31, 2023), against $2.2 million the year before (-17.9%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Inhibrx, Inc.'s operating income in fiscal 2023?
- Inhibrx, Inc. reported operating income of -$219.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$129.1 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Inhibrx, Inc.'s net income in fiscal 2023?
- Inhibrx, Inc. reported net income of -$241.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$145.2 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Inhibrx, Inc.'s cash from operating activities in fiscal 2023?
- Inhibrx, Inc. reported cash from operating activities of -$193.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$115.3 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Inhibrx, Inc.'s free cash flow in fiscal 2023?
- Inhibrx, Inc. reported free cash flow of -$197.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$116 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What are Inhibrx, Inc.'s total assets?
- As of Dec 31, 2023, Inhibrx, Inc. reported total assets of $307.9 million, against $290.9 million a year earlier (+5.9%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What are Inhibrx, Inc.'s total liabilities?
- As of Dec 31, 2023, Inhibrx, Inc. reported total liabilities of $264.4 million, against $232.8 million a year earlier (+13.6%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What are Inhibrx, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Inhibrx, Inc. reported cash and cash equivalents of $277.9 million, against $273.9 million a year earlier (+1.5%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What is Inhibrx, Inc.'s total debt?
- As of Dec 31, 2023, Inhibrx, Inc. reported total debt of $207 million. Source: the 10-Q filed with the SEC on May 9, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1739614&period_type=annual&limit=5"Information only, not investment advice.